Research programme : anti-fibrotics - Pliant Therapeutics

Drug Profile

Research programme : anti-fibrotics - Pliant Therapeutics

Latest Information Update: 10 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pliant Therapeutics
  • Class Small molecules
  • Mechanism of Action Emt protein-tyrosine kinase modulators; Integrin modulators; TGF-beta superfamily protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis

Most Recent Events

  • 18 Feb 2016 Preclinical trials in Fibrosis in USA (unspecified route)
  • 01 Feb 2016 Pliant announces intention to submit IND in 2017 (Pliant's pipeline, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top